Future Advances in Melanoma Research

Clinics in Plastic Surgery

Volumn 37, Issue 1, 2010, Pages 169-176

  Hornyak, Thomas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer stem cell; Melanocyte; Melanoma; Nevus; Oncogene; Senescence

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN;

CANCER RESEARCH; CANCER STEM CELL; CANCER SUSCEPTIBILITY; CELL ONCOGENE; COMPARATIVE GENOMIC HYBRIDIZATION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SEQUENCE; GENOME ANALYSIS; HUMAN; MELANOMA; MELANOMA CELL; PROTEIN TARGETING; REVIEW; SENESCENCE; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TARGET CELL;

BIOMEDICAL RESEARCH; COMPARATIVE GENOMIC HYBRIDIZATION; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MELANOMA; MUTATION; NEOPLASTIC STEM CELLS; SKIN NEOPLASMS;

EID: 70449333266     PISSN: 00941298     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cps.2009.07.005     Document Type: Review

References (58)

1. Chin L., Garraway L.A., and Fisher D.E. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 20 (2006) 2149-2182
2. Davies H., Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
3. Gray-Schopfer V.C., Cheong S.C., Chong H., et al. Cellular senescence in naevi and immortalisation in melanoma: a role for p16?. Br J Cancer 95 (2006) 496-505
4. Michaloglou C., Vredeveld L.C., Soengas M.S., et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436 (2005) 720-724
5. Papp T., Pemsel H., Zimmermann R., et al. Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi. J Med Genet 36 (1999) 610-614
6. Pollock P.M., Harper U.L., Hansen K.S., et al. High frequency of BRAF mutations in nevi. Nat Genet 33 (2003) 19-20
7. Fang D., Nguyen T.K., Leishear K., et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65 (2005) 9328-9337
8. Schatton T., Murphy G.F., Frank N.Y., et al. Identification of cells initiating human melanomas. Nature 451 (2008) 345-349
9. Dudley M.E., Wunderlich J.R., Robbins P.F., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298 (2002) 850-854
10. Morgan R.A., Dudley M.E., Wunderlich J.R., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314 (2006) 126-129
11. Goldstein A.M., Chan M., Harland M., et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 66 (2006) 9818-9828
12. Hussussian C.J., Struewing J.P., Goldstein A.M., et al. Germline p16 mutations in familial melanoma. Nat Genet 8 (1994) 15-21
13. Kamb A., Shattuck-Eidens D., Eeles R., et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8 (1994) 23-26
14. Walker G.J., Flores J.F., Glendening J.M., et al. Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets. Genes Chromosomes Cancer 22 (1998) 157-163
15. Bennett D.C., Cooper P.J., and Hart I.R. A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth. Int J Cancer 39 (1987) 414-418
16. Sviderskaya E.V., Hill S.P., Evans-Whipp T.J., et al. p16(Ink4a) in melanocyte senescence and differentiation. J Natl Cancer Inst 94 (2002) 446-454
17. Chin L., Pomerantz J., Polsky D., et al. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev 11 (1997) 2822-2834
18. Noonan F.P., Recio J.A., Takayama H., et al. Neonatal sunburn and melanoma in mice. Nature 413 (2001) 271-272
19. Box N.F., Duffy D.L., Chen W., et al. MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 69 (2001) 765-773
20. Rees J.L. Genetics of hair and skin color. Annu Rev Genet 37 (2003) 67-90
21. Valverde P., Healy E., Sikkink S., et al. The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Hum Mol Genet 5 (1996) 1663-1666
22. Goldstein A.M., Fraser M.C., Struewing J.P., et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 333 (1995) 970-974
23. Parada L.F., Tabin C.J., Shih C., et al. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature 297 (1982) 474-478
24. van 't Veer L.J., Burgering B.M., Versteeg R., et al. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol 9 (1989) 3114-3116
25. Tsao H., Goel V., Wu H., et al. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 122 (2004) 337-341
26. Maldonado J.L., Fridlyand J., Patel H., et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 95 (2003) 1878-1890
27. Curtin J.A., Fridlyand J., Kageshita T., et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 353 (2005) 2135-2147
28. Samuels Y., Wang Z., Bardelli A., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304 (2004) 554
29. Samuels Y., Diaz Jr. L.A., Schmidt-Kittler O., et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7 (2005) 561-573
30. Parsons D.W., Wang T.L., Samuels Y., et al. Colorectal cancer: mutations in a signalling pathway. Nature 436 (2005) 792
31. Ley T.J., Mardis E.R., Ding L., et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456 (2008) 66-72
32. Palavalli L.H., Prickett T.D., Wunderlich J.R., et al. Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat Genet 41 (2009) 518-520
33. Hingorani S.R., Jacobetz M.A., Robertson G.P., et al. Suppression of BRAF (V599E) in human melanoma abrogates transformation. Cancer Res 63 (2003) 5198-5202
34. Wellbrock C., Ogilvie L., Hedley D., et al. V599EB-RAF is an oncogene in melanocytes. Cancer Res 64 (2004) 2338-2342
35. Eisen T., Ahmad T., Flaherty K.T., et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 95 (2006) 581-586
36. Campisi J., and d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 8 (2007) 729-740
37. Serrano M., Lin A.W., McCurrach M.E., et al. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88 (1997) 593-602
38. Wajapeyee N., Serra R.W., Zhu X., et al. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 132 (2008) 363-374
39. Kuilman T., Michaloglou C., Vredeveld L.C., et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133 (2008) 1019-1031
40. Bauer J., and Bastian B.C. Distinguishing melanocytic nevi from melanoma by DNA copy number changes: comparative genomic hybridization as a research and diagnostic tool. Dermatol Ther 19 (2006) 40-49
41. Bastian B.C., Olshen A.B., LeBoit P.E., et al. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol 163 (2003) 1765-1770
42. Bastian B.C., LeBoit P.E., and Pinkel D. Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. Am J Pathol 157 (2000) 967-972
43. Bastian B.C., Xiong J., Frieden I.J., et al. Genetic changes in neoplasms arising in congenital melanocytic nevi: differences between nodular proliferations and melanomas. Am J Pathol 161 (2002) 1163-1169
44. Curtin J.A., Busam K., Pinkel D., et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24 (2006) 4340-4346
45. Hodi F.S., Friedlander P., Corless C.L., et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 26 (2008) 2046-2051
46. Lutzky J., Bauer J., and Bastian B.C. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res 21 (2008) 492-493
47. Murphy M.J., Jen M., Chang M.W., et al. Molecular diagnosis of a benign proliferative nodule developing in a congenital melanocytic nevus in a 3-month-old infant. J Am Acad Dermatol 59 (2008) 518-523
48. Garraway L.A., Widlund H.R., Rubin M.A., et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436 (2005) 117-122
49. Lapidot T., Sirard C., Vormoor J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367 (1994) 645-648
50. Al-Hajj M., Wicha M.S., Benito-Hernandez A., et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100 (2003) 3983-3988
51. Monzani E., Facchetti F., Galmozzi E., et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 43 (2007) 935-946
52. Frank N.Y., Margaryan A., Huang Y., et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 65 (2005) 4320-4333
53. Quintana E., Shackleton M., Sabel M.S., et al. Efficient tumour formation by single human melanoma cells. Nature 456 (2008) 593-598
54. O'Brien C.A., Pollett A., Gallinger S., et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445 (2007) 106-110
55. Dave S.S., Wright G., Tan B., et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351 (2004) 2159-2169
56. Winnepenninckx V., Lazar V., Michiels S., et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 98 (2006) 472-482
57. Winnepenninckx V., and van den Oord J.J. Gene expression profiling and clinical outcome in melanoma: in search of novel prognostic factors. Expert Rev Anticancer Ther 7 (2007) 1611-1631
58. Kirkwood J.M., Tarhini A.A., Panelli M.C., et al. Next generation of immunotherapy for melanoma. J Clin Oncol 26 (2008) 3445-3455